Skip to main content
. 2016 Feb 17;7(12):15243–15251. doi: 10.18632/oncotarget.7444

Table 2. Best objective response to sorafenib.

All patients (n=61) No. (%) No HTN (n=35) No. (%) HTN (n=26) No. (%) p
CR 1 (2.0) 0 1 (4.5)
PR 3 (5.9) 0 3 (13.6)
SD 15 (29.4) 5 (17.2) 10 (45.5)
PD 32 (62.7) 24 (82.8) 8 (36.4)
Missing/NE 10 6 4
DCR (CR+PR+SD) 19 (37.3) 5 (17.2) 14 (63.4) 0.001

HTN, hypertension; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; DCR, disease control rate